NasdaqGS:SDGRHealthcare Services
Schrödinger (SDGR) Valuation in Focus After Halting SGR-2921 Development Following Safety Concerns
Schrödinger (SDGR) is making waves today after announcing it will discontinue development of its CDC7 inhibitor, SGR-2921, following two patient deaths linked to the drug in an early-stage study for acute myeloid leukemia. Investors who have tracked the company’s clinical pipeline will recognize this decision as significant, both for its near-term impact and what it signals about the company’s drug discovery strategy. Although the Phase 1 study showed some hints of activity, safety concerns...